Adageis Drives Value-Based Care Transition as Healthcare Switches from Artificial General Intelligence to Specific Use Cases

• Healthcare providers are increasingly prioritizing specific, high-impact AI applications that enhance patient care and financial performance.
• Adageis’ ProActive Care Platform leverages AI to enhance risk assessment, workflow optimization, and revenue tracking for providers.
• AI-driven patient monitoring and early intervention reduce hospital readmissions and improve care quality.
• Adageis’ Patented Risk Engine helps healthcare providers proactively address high-risk patients, improving outcomes while increasing reimbursements.
• Seamless integration with multiple EHR systems ensures easy adoption without disrupting provider workflows.

As in other areas, artificial intelligence is making a measurable impact on healthcare, but the focus is shifting. While artificial general intelligence (“AGI”) once dominated AI discussions, healthcare providers are now increasingly prioritizing specific, high-impact AI use cases and applications that enhance patient care and financial performance. This transition is being driven by value-based care models, which require providers to demonstrate improved patient outcomes rather than simply increasing service volume.

Companies like Adageis, a leading healthcare technology company, are at the forefront of this shift, delivering AI-driven tools that optimize patient care, track revenue, and improve operational efficiency. Adageis develops AI-centric solutions tailored to providers, Accountable Care Organizations (“ACOs”), and Clinically Integrated Networks (“CINs”). Its ProActive Care Platform is designed to integrate seamlessly into existing workflows, offering practical applications that directly impact revenue generation and patient care.

Key areas where Adageis’ AI solutions are making a difference:

• Risk Identification & Early Intervention: The Patented Risk Engine analyzes patient data to identify individuals at risk for chronic diseases or complications. By flagging high-risk patients early, providers can proactively intervene, reducing hospital readmissions and lowering costs.
• Revenue Tracking & Forecasting: Adageis simplifies value-based care revenue management by providing real-time insights into provider performance. AI-driven analytics ensure accurate revenue tracking across multiple providers, making it easier to align with payer incentives.
• Clinical Decision Support: The platform integrates with nearly 100 electronic health record (“EHR”) systems like AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, offering real-time insights at the point of care. This ensures that clinicians receive actionable recommendations without disrupting workflows.
• Administrative Task Automation: Beyond clinical applications, Adageis helps providers manage supply chains, resource allocation, and documentation, increasing efficiency and reducing administrative burdens.
• Continuous Patient Monitoring: AI-powered efficiency monitoring tools allow real-time tracking of patient health trends, ensuring timely interventions between visits. This leads to fewer emergency department visits and better overall patient outcomes.

The healthcare industry’s transition to value-based care is well underway, but many providers struggle with the financial complexities of this model. AI tools like those developed by Adageis help organizations meet value-based care metrics, ensuring they maximize reimbursements while improving patient care.

Adageis’ Value-Based Care Engine provides automated performance tracking to ensure compliance with payer requirements, optimized patient care strategies that improve reimbursement rates, as well as advanced analytics that help providers predict and manage costs. By streamlining complex processes, Adageis makes it easier for healthcare organizations to generate revenue while improving patient outcomes.

As AI continues to evolve, the shift from AGI to highly targeted applications in healthcare will accelerate. Companies like Adageis are demonstrating how AI can deliver tangible results, helping providers navigate the challenges of value-based care with precision and efficiency, improving financial performance, and enhancing patient outcomes—all without adding complexity to providers’ workflows.

“We offer a solution that meets everyone’s needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with,” Adageis CEO Shane Speirs said recently. “Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN